Skip to search formSkip to main contentSkip to account menu

CBM 4A

Known as: CBM-4A 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

chlorobromofosfamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Activity and Distribution of Cells Infiltrating TC-1 Tumours after Chemotherapy and Subsequent IL-12 Immunotherapy
Methods: Moderately immunogenic HPV-16-associated TC-1 tumour mimicking human HPV-16-associated neoplasms was used to examine the… 
2007
2007
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this… 
2006
2006
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Moderately immunogenic HPV 16-associated murine tumour cell line mimicking human HPV 16-associated neoplasms TC-1 (MHC class I… 
2004
2004
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Moderately immunogenic HPV16-associated tumours TC-1 (MHC class I+, HPV16 E6/E7+, G12V Ha-ras+) and MK16/1/IIIABC (MK16, MHC… 
2003
2003
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
The effectiveness of chemoimmunotherapy with ifosfamide derivative CBM-4A and recombinant IL-2, IL-12, GM-CSF, or genetically… 
2001
2001
Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A.
The effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and granulocyte-macrophage colony-stimulating… 
1995
1995
Growth inhibition of transplantable tumors in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent.
The non-tumorigenic cells of X63-Ag8.653 mouse plasmocytoma line transfected with murine interleukin 2 cDNA (X63-mIL-2) served us… 
1994
1994
Pharmacological properties of racemic chlorobromofosfamide.
Racemic chlorobromofosfamide (CBM-4A) is a bromine substituted analog of ifosfamide. The studies reported here were aimed at… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)